期刊文献+

DC/CIK细胞治疗152例肿瘤的副反应观察 被引量:2

Observation of side effects of cancer patients receiving DC/CIK cell therapy in 152 cases
下载PDF
导出
摘要 目的探讨树突状细胞与细胞因子诱导的杀伤细胞(DC/CIK细胞)治疗的副反应。方法回顾性分析152例接受DC/CIK细胞治疗的癌症患者的临床资料。结果 152例患者中,肝功能异常13例,发生率为8.6%。肾功能异常12例,发生率为7.9%。心电图异常15例,发生率为9.9%。贫血8例,发生率为5.3%。发热16例,发生率为10.5%。无治疗相关性死亡。结论 DC/CIK细胞治疗可引起轻度副反应。但是,如果不给予高度重视,早期发现,早期处理,则可能导致严重后果。 Objective To explore the side effects of dendritic cells and cell factors induced the killer cell (DC/CIK cells) treatment. Methods The clinical data of 152 cases of cancer patients receiving DC/CIK cell therapy were retrospectively analyzed. Results In the 152 patients, there were 13 cases of abnormal liver function, the rate of 8.6%. 12 cases of renal dysfunction, the rate of 7.9%. 15 cases of ECG abnormalities, the rate of 9.9%. 8 cases of anemia, the rate of 5.3% and 16 cases of fever, the rate of 10.5%. There was not treatment-related death. Conclusion DC/CIK cell therapy can cause mild side effects. However, if you do not attach great importance to early detection and early treatment, it may lead to serious consequences.
出处 《中国当代医药》 2013年第1期6-8,共3页 China Modern Medicine
基金 吴阶平医学基金会临床科研专项资助基金(编号:320.6799.1096)
关键词 肿瘤 树突状细胞 细胞因子诱导的杀伤细胞 副反应 Tumor Dendritic cell Cytokine induced killer cell Side effects
  • 相关文献

参考文献25

  • 1Freddie Bray,Ahmedin Jemal,Nathan Grey,et al.Global cancer transitions according to the Human Development Index (2008-2030):a population-based study[J].The Lancet Oncology,2012,13(8):790-801. 被引量:1
  • 2Jiang He,Dongfeng Gu,Xigui Wu,et al.Major causes of death among men and women in China[J].The New England Journal of Medicine,2005,353(11):1123-1134. 被引量:1
  • 3DeVita VT,Rosenberg SA.Two hundred years of cancer research[J].N Engl J Med,2012,366:2207-2214. 被引量:1
  • 4殷蔚伯,余子豪,徐国镇,胡逸民主编..肿瘤放射治疗学 第4版[M].北京:中国协和医科大学出版社,2008:1374.
  • 5Porter DL,Hexner EO,Cooley S,et al.Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation[J].Cancer Treat Res,2009,144(2):497-537. 被引量:1
  • 6Schmidt-Wolf IG,Lef terova P,Mehta BA,et al.Phenotypic characterization and identification of effect or cells involved in tumor cell recognition of cytokine-induced killer cells[J].Exp Hematol,1993,21(13):1673-1679. 被引量:1
  • 7Erhadt M,Schmidt-Wolf IG,Sievers E,et al.Anti-tumoral capabilities of effector cells after IFN-alpha or CpG-motif treatment of cocultured dendritic cells[J].Arch Immunol Ther Exp(Warsz),2006,54(6):403-409. 被引量:1
  • 8Yamaguchi Y,Ohshita A,Kawabuchi Y.Adoptive immunotherapy of cancer using activated autologous lymphocytes-current status and new strateg[J].Hum Cell,2003,16(4):183-189. 被引量:1
  • 9Li H,Wang C,Yu J,et al.Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery[J].Cytotherapy,2009,11(8):1076-1083. 被引量:1
  • 10金惠铭,王建枝.病理生理学[M].7版.北京:人民卫生出版社,2008:80-81. 被引量:9

二级参考文献14

  • 1王君艳,王常青,刘景华.重组人白介素-Ⅱ治疗恶性肿瘤副作用15例的护理体会[J].四川肿瘤防治,2004,17(3):192-193. 被引量:1
  • 2李海珠,高萌,曲云翠,于连红,张恩芳.肺癌患者IL-2/LAK细胞过继免疫疗法的护理[J].佳木斯医学院学报,1995,18(5):26-27. 被引量:3
  • 3Lee RE,Lotze MT,Skibber JM,et al.Cardiorespiratory effects of immunotherapy with interleukin 2[J].J Clin Oncol,1989,7(1):7-20. 被引量:1
  • 4Beck AC,Ward JH,Hammond EH,et al.Cardiomyopathy associated with high-dose interleukin-2 therapy[J].Western J Med,1991,155(9):293-296. 被引量:1
  • 5Shaw C. Nutrition and cancer[M].Oxford UK:Wiley-Blackwell,2011. 被引量:1
  • 6Huang Z,Huang S,Wang Q. MicroRNA-95 promotes cell proliferation and targets sorting nexin 1 in human colorectal carcinoma[J].Cancer Research,2011,(07):2582-2589. 被引量:1
  • 7Cao DX,Wu GH,Yang ZA. Role of (1-adrenoceptor in increased lipolysis in cancer cachexia[J].Cancer Science,2010,(07):1639-1645. 被引量:1
  • 8Cao DX,Wu GH,Zhang B. Resting energy expenditure and body composition in patients with newly detected cancer[J].Clinical Nutrition,2010,(01):72-77. 被引量:1
  • 9August DA,Huhmann MB. A.S.P.E.N.clinical guidelines:nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation[J].Journal of Parenteral and Enteral Nutrition,2009,(05):472-500. 被引量:1
  • 10Bozzetti F,Arends J,Lundholm K. ESPEN guidelines on parenteral nutrition:non-surgical oncology[J].Clinical Nutrition,2009,(04):445-454. 被引量:1

共引文献61

同被引文献26

  • 1蒋东霞,杨晓博,赵婷茹,徐虹,胡杰英,宋永平.CIK细胞体外逆转多药耐药性的研究[J].河南医学研究,2008,17(1):20-22. 被引量:7
  • 2秦莉,王志华.CIK细胞的体外培养与细胞毒作用[J].医学分子生物学杂志,2007,4(1):82-85. 被引量:16
  • 3孙燕 周际昌.临床肿瘤内科手册[M].北京:人民卫生出版社,2003.586-591. 被引量:387
  • 4Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC) [ J ]. J Cancer Res Clin Oncol, 2011,137 (2) : 305- 310. 被引量:1
  • 5孙燕,汤钊猷.UICC临床肿瘤学手册[M].8版.北京:人民卫生出版社,2006:425-501. 被引量:1
  • 6Hoheika A C, Morse M A, Osada T, et al. Depletion of hu- man regulatory T cells[J]. Methods Mol Biol, 2011,707:219- 231. 被引量:1
  • 7Kim Y J, Lim J, Kang J S, et al. Adoptive immunothe of human gastric cancer with ex vivo expanded T cells[ J]. Arch Pharm Res, 2010,33 ( 11 ) : 1789-1795. 被引量:1
  • 8Schoenfeld J, Jinushi M, Nakazaki Y, et al. Active immu- notherapy induces antibody responses that target tumor angio- genesis[J]. Cancer Res, 2010,70(24) :10150-10160. 被引量:1
  • 9Gomes A Q, Martins D S, Silva-Santos B. TargetingγδT lymphocytes for cancer immunotherapy:from novel mechanis- tic insight to clinical application [ J ]. Cancer Res, 2010,70 (24) : 10024-10027. 被引量:1
  • 10Olioso P, Giancola R, Di Riti M, et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours :a pilot clinical trial [ J ]. Hematol Oncol, 2009,27(3):130-139. 被引量:1

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部